Insurance systems and reimbursement concerning research and development of regenerative medicine in Japan

Kiyoshi Okada*, Toshio Miyata, Yoshiki Sawa

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

10 Citations (Scopus)

Abstract

In Japan, the Act on the Safety of Regenerative Medicine and the Pharmaceuticals, Medical Devices and Other Therapeutic Products Act were enacted in November 2014, creating a new framework for clinical research and products related to regenerative medicine. Together with these regulatory frameworks, new insurance procedures were created for handling regenerative medicine in Japan. For developing regenerative medicine in Japan, understanding medical insurance greatly influences funding and venture success, particularly in the stages between clinical research and market launch. The study aimed to identify the issues and examples surrounding Japan's present medical insurance system, especially for regenerative medicine. We believe that building stronger insurance systems for regenerative medicine is essential for internationally aligning and harmonizing the progress of regenerative medicine.

Original languageEnglish
Pages (from-to)179-186
Number of pages8
JournalRegenerative Medicine
Volume12
Issue number2
DOIs
Publication statusPublished - 2017 Mar
Externally publishedYes

Keywords

  • heartsheet
  • JACC
  • JACE
  • public health insurance
  • regulation
  • reimbursement
  • temcell HS

ASJC Scopus subject areas

  • Biomedical Engineering
  • Embryology

Fingerprint

Dive into the research topics of 'Insurance systems and reimbursement concerning research and development of regenerative medicine in Japan'. Together they form a unique fingerprint.

Cite this